Clinical trials in Huntington's disease: Interventions in early clinical development and newer methodological approaches
出版年份 2014 全文链接
标题
Clinical trials in Huntington's disease: Interventions in early clinical development and newer methodological approaches
作者
关键词
-
出版物
MOVEMENT DISORDERS
Volume 29, Issue 11, Pages 1419-1428
出版商
Wiley
发表日期
2014-09-12
DOI
10.1002/mds.26021
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- A potent and selective Sirtuin 1 inhibitor alleviates pathology in multiple animal and cell models of Huntington's disease
- (2014) Marianne R. Smith et al. HUMAN MOLECULAR GENETICS
- Deep brain stimulation for Huntington's disease: long-term results of a prospective open-label study
- (2014) Victoria Gonzalez et al. JOURNAL OF NEUROSURGERY
- HD-CAB: A cognitive assessment battery for clinical trials in Huntington's disease1,2,3
- (2014) Julie C. Stout et al. MOVEMENT DISORDERS
- Clinical development success rates for investigational drugs
- (2014) Michael Hay et al. NATURE BIOTECHNOLOGY
- Huntington disease: natural history, biomarkers and prospects for therapeutics
- (2014) Christopher A. Ross et al. Nature Reviews Neurology
- PRECREST: A phase II prevention and biomarker trial of creatine in at-risk Huntington disease
- (2014) H. D. Rosas et al. NEUROLOGY
- Genetic Deletion of Transglutaminase 2 Does Not Rescue the Phenotypic Deficits Observed in R6/2 and zQ175 Mouse Models of Huntington's Disease
- (2014) Liliana B. Menalled et al. PLoS One
- Alzheimer’s disease drug-development pipeline: few candidates, frequent failures
- (2014) Jeffrey L Cummings et al. Alzheimers Research & Therapy
- Cysteamine: an old drug with new potential
- (2013) Martine Besouw et al. DRUG DISCOVERY TODAY
- An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study
- (2013) Timothy M Miller et al. LANCET NEUROLOGY
- Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data
- (2013) Sarah J Tabrizi et al. LANCET NEUROLOGY
- The pridopidine paradox in Huntington's disease
- (2013) Ralf Reilmann MOVEMENT DISORDERS
- A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington's disease
- (2013) MOVEMENT DISORDERS
- A 5-year follow-up of deep brain stimulation in Huntington's disease
- (2013) Jose Luis López-Sendón Moreno et al. PARKINSONISM & RELATED DISORDERS
- Q02 A randomised, double-blind, placebo-controlled phase IB pharmacodynamic study with selisistat (SEN0014196) in HD patients
- (2012) SD Süssmuth et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Cognitive domains that predict time to diagnosis in prodromal Huntington disease
- (2012) Deborah Lynn Harrington et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Evaluation of longitudinal 12 and 24 month cognitive outcomes in premanifest and early Huntington's disease
- (2012) Julie C Stout et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Longitudinal Evaluation of Neuropsychiatric Symptoms in Huntington's Disease
- (2012) Jennifer C. Thompson et al. JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES
- Characterization of a Large Group of Individuals with Huntington Disease and Their Relatives Enrolled in the COHORT Study
- (2012) E. Ray Dorsey et al. PLoS One
- Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival
- (2011) Paul Morgan et al. DRUG DISCOVERY TODAY
- Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial
- (2011) Justo Garcia de Yebenes et al. LANCET NEUROLOGY
- An item response analysis of the motor and behavioral subscales of the unified Huntington's disease rating scale in huntington disease gene expansion carriers
- (2011) Anthony L. Vaccarino et al. MOVEMENT DISORDERS
- Pharmacologic approaches to the treatment of Huntington's disease
- (2011) Charles S. Venuto et al. MOVEMENT DISORDERS
- Assessment of involuntary choreatic movements in Huntington's disease-Toward objective and quantitative measures
- (2011) Ralf Reilmann et al. MOVEMENT DISORDERS
- Benefits, challenges and obstacles of adaptive clinical trial designs
- (2011) Shein-Chung Chow et al. Orphanet Journal of Rare Diseases
- Chronic Suppression of Phosphodiesterase 10A Alters Striatal Expression of Genes Responsible for Neurotransmitter Synthesis, Neurotransmission, and Signaling Pathways Implicated in Huntington's Disease
- (2010) R. J. Kleiman et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis
- (2010) Sarah J Tabrizi et al. LANCET NEUROLOGY
- Tongue force analysis assesses motor phenotype in premanifest and symptomatic Huntington's disease
- (2010) Ralf Reilmann et al. MOVEMENT DISORDERS
- Grasping premanifest Huntington's disease - shaping new endpoints for new trials
- (2010) Ralf Reilmann et al. MOVEMENT DISORDERS
- Tapping linked to function and structure in premanifest and symptomatic Huntington disease
- (2010) N. Bechtel et al. NEUROLOGY
- Potential of cystamine and cysteamine in the treatment of neurodegenerative diseases
- (2010) C. Gibrat et al. PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
- Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data
- (2009) Sarah J Tabrizi et al. LANCET NEUROLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started